Activated protein C, a protein at the crossroads between coagulation and inflammation;La protéine C activée Une protéine à l'interface de l'inflammation et de la coagulation

Medecine/Sciences

Volumn 27, Issue 5, 2011, Pages 501-507

  Borgel, Delphine ^a,b   Vieillard Baron, Antoine ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

^b EA 4531 Ingenierie des Proteines de l'Hemostase A Potentiel Therapeutique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; CELL SURFACE RECEPTOR; HISTONE; HYBRID PROTEIN; LEUKOCYTE ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROCR PROTEIN, HUMAN; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1;

ANIMAL; BIOLOGICAL MODEL; BLEEDING DISORDER; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; FIBRINOLYSIS; HUMAN; INFLAMMATION; LEUKOCYTE ROLLING; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SECRETION; SEPSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ANTIGENS, CD; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FIBRINOLYSIS; HEMORRHAGIC DISORDERS; HISTONES; HUMANS; INFLAMMATION; LEUKOCYTE ROLLING; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; PROTEIN C; RECEPTOR, PAR-1; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SEPSIS;

EID: 79958725703     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2011275015     Document Type: Review

References (42)

1. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6. (Pubitemid 19092874)
2. Gandrille S, Saposnik B, Aiach M. Le récepteur endothelial à la protéine C (EPCR) : un récepteur à l'interface entre coagulation et système inflammatoire. Hématologie 2001; 7: 418-28. (Pubitemid 34211525)
3. Esmon CT, Fukudome K. Cellular regulation of the protein C pathway. Semin Cell Biol 1995; 6: 259-68.
4. Dahlback B. Protein S and C4b-binding protein : components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61.
5. Aiach M, Alhenc-Gelas M, Borgel D, et al. Mutations des protéines de la coagulation et thromboses. Med Sci (Paris) 2006; 22: 985-9.
6. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567-70.
7. Vincent JL, Sakr y, Sprung CL, et al. Sepsis in European intensive care units : results of the SOAP study. Crit Care Med 2006; 34: 344-53.
8. Guha M, Madman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13: 85-94. (Pubitemid 32222977)
9. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29: S90-4. (Pubitemid 32681588)
10. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010; 38: S35-42.
11. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15: 254-9. (Pubitemid 41437908)
12. van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-9. (Pubitemid 24091784)
13. Jansen PM, Boermeester MA, Fischer E, et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis : studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995; 86: 1027-34.
14. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88: 1346-53.
15. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 1: 1343-8.
16. McLaughlin JN, Shen L, Holinstat M, et al. Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 2005; 280: 25048-59. (Pubitemid 40934596)
17. Joyce DE, Nelson DR, Grinnell BW. Leukocyte and endothelial cell interactions in sepsis : relevance of the protein C pathway. Crit Care Med 2004; 32: S280-6.
18. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178-84.
19. Sturn DH, Kaneider NC, Feistritzer C, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102: 1499-505. (Pubitemid 36988062)
20. Elphick GF, Sarangi PP, Hyun YM, et al. Recombinant human activated protein C inhibits integrinmediated neutrophil migration. Blood 2009; 113: 4078-85.
21. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2. (Pubitemid 34596276)
22. Coo C, Gao Y, Li Y, et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010; 120: 1971-80.
23. Mahidhara R, Billiar TR. Apoptosis in sepsis. Crit Care Med 2000; 28: N105-13.
24. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101: 3765-77. (Pubitemid 36857845)
25. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-42. (Pubitemid 36362790)
26. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol 2006; 177: 2115-22. (Pubitemid 44200969)
27. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196: 565-77. (Pubitemid 35024436)
28. Anderson HA, Maylock CA, Williams JA, et al. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003; 4: 87-91. (Pubitemid 36113217)
29. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15: 1318-21.
30. Viatte L Dr Jekyll et Mr Histone: protéger ou tuer, la dualité des histones. Med Sci (Paris) 2010; 26: 144.
31. Shorr AF, Bernard GR, Dhainaut JF, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 2006; 10: R92.
32. Taylor FB, Jr., Chang A, Esmon CT, et aL. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
33. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439-48. (Pubitemid 47529328)
34. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709. (Pubitemid 32204987)
35. Ely EW, Laterre PF, Angus DC et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31: 12-9. (Pubitemid 36151143)
36. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33: 2266-77. (Pubitemid 41437481)
37. Payen D, Sundin DP, Nelson DR, Williams MD. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database. Surgery 2007; 142: 426-7. (Pubitemid 47307359)
38. Thompson BT, Ranieri VM, Finfer S, et al. Statistical analysis plan of PROWESS SHOCK study. Intensive Care Med 2010; 36: 1972-3.
39. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-41. (Pubitemid 41362701)
40. Carlet J. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise. Crit Care Med 2006; 34: 525-9. (Pubitemid 43145633)
41. Vieillard-Baron A, Caille V., Charron C, et al. Reversal of refractory septic shock with drotrecogin alpha (activated). Intensive Care Med 2009; 35: 1204-9.
42. Dumont B, Faille D, Ajzenberg N. Les nouveaux anticoagulants oraux: dabigatran, rivaroxaban et apixaban. Leur utilisation actuelle et leur avenir. Med Sci (Paris) 2011; 27: 493-500.